Stock Price

299,20 SEK

17.01% ROA

2.34% ROE

101.38x PER

Market Cap.

40.754.132.790,00 SEK

11.14% DER

0.28% Yield

11.61% NPM

Vitrolife AB (publ) Stock Analysis

Vitrolife AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Vitrolife AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Vitrolife AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Vitrolife AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Vitrolife AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Vitrolife AB (publ) Revenue
Year Revenue Growth
2012 362.020.000
2013 452.738.000 20.04%
2014 510.512.000 11.32%
2015 722.370.000 29.33%
2016 856.106.000 15.62%
2017 1.046.217.000 18.17%
2018 1.151.348.000 9.13%
2019 1.480.132.000 22.21%
2020 1.245.572.000 -18.83%
2021 1.681.000.000 25.9%
2022 3.234.000.000 48.02%
2023 3.392.000.000 4.66%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Vitrolife AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2012 41.204.000
2013 58.874.000 30.01%
2014 38.835.000 -51.6%
2015 81.894.000 52.58%
2016 96.737.000 15.34%
2017 116.063.000 16.65%
2018 119.685.000 3.03%
2019 143.359.000 16.51%
2020 121.279.000 -18.21%
2021 140.000.000 13.37%
2022 228.000.000 38.6%
2023 124.000.000 -83.87%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Vitrolife AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 45.170.000
2013 55.891.000 19.18%
2014 59.960.000 6.79%
2015 80.467.000 25.48%
2016 94.146.000 14.53%
2017 99.334.000 5.22%
2018 99.270.000 -0.06%
2019 119.382.000 16.85%
2020 114.424.000 -4.33%
2021 259.000.000 55.82%
2022 400.000.000 35.25%
2023 384.000.000 -4.17%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Vitrolife AB (publ) EBITDA
Year EBITDA Growth
2012 68.274.000
2013 109.109.000 37.43%
2014 152.749.000 28.57%
2015 241.208.000 36.67%
2016 292.198.000 17.45%
2017 392.944.000 25.64%
2018 457.951.000 14.2%
2019 559.571.000 18.16%
2020 420.879.000 -32.95%
2021 506.000.000 16.82%
2022 991.000.000 48.94%
2023 1.156.000.000 14.27%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Vitrolife AB (publ) Gross Profit
Year Gross Profit Growth
2012 238.300.000
2013 300.555.000 20.71%
2014 349.118.000 13.91%
2015 484.820.000 27.99%
2016 561.301.000 13.63%
2017 681.709.000 17.66%
2018 761.124.000 10.43%
2019 938.652.000 18.91%
2020 767.667.000 -22.27%
2021 1.046.000.000 26.61%
2022 1.780.000.000 41.24%
2023 1.892.000.000 5.92%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Vitrolife AB (publ) Net Profit
Year Net Profit Growth
2012 26.256.000
2013 56.274.000 53.34%
2014 109.109.000 48.42%
2015 182.845.000 40.33%
2016 190.368.000 3.95%
2017 263.640.000 27.79%
2018 309.697.000 14.87%
2019 382.785.000 19.09%
2020 286.845.000 -33.45%
2021 341.000.000 15.88%
2022 394.000.000 13.45%
2023 488.000.000 19.26%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Vitrolife AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 1 0%
2014 1 100%
2015 2 0%
2016 2 0%
2017 2 50%
2018 3 0%
2019 4 33.33%
2020 3 -50%
2021 3 0%
2022 3 0%
2023 4 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Vitrolife AB (publ) Free Cashflow
Year Free Cashflow Growth
2012 44.880.000
2013 99.468.000 54.88%
2014 139.643.000 28.77%
2015 183.987.000 24.1%
2016 171.293.000 -7.41%
2017 302.687.000 43.41%
2018 331.025.000 8.56%
2019 394.238.000 16.03%
2020 349.679.000 -12.74%
2021 359.000.000 2.6%
2022 585.000.000 38.63%
2023 182.000.000 -221.43%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Vitrolife AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2012 59.930.000
2013 106.127.000 43.53%
2014 145.666.000 27.14%
2015 193.526.000 24.73%
2016 181.262.000 -6.77%
2017 312.189.000 41.94%
2018 349.435.000 10.66%
2019 413.333.000 15.46%
2020 356.448.000 -15.96%
2021 384.000.000 7.18%
2022 636.000.000 39.62%
2023 214.000.000 -197.2%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Vitrolife AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2012 15.050.000
2013 6.659.000 -126.01%
2014 6.023.000 -10.56%
2015 9.539.000 36.86%
2016 9.969.000 4.31%
2017 9.502.000 -4.91%
2018 18.410.000 48.39%
2019 19.095.000 3.59%
2020 6.769.000 -182.09%
2021 25.000.000 72.92%
2022 51.000.000 50.98%
2023 32.000.000 -59.38%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Vitrolife AB (publ) Equity
Year Equity Growth
2012 278.982.000
2013 315.529.999 11.58%
2014 702.571.000 55.09%
2015 844.972.000 16.85%
2016 1.020.384.000 17.19%
2017 1.228.649.000 16.95%
2018 1.496.212.000 17.88%
2019 1.797.628.000 16.77%
2020 2.017.014.000 10.88%
2021 15.341.000.000 86.85%
2022 16.740.000.000 8.36%
2023 17.431.000.000 3.96%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Vitrolife AB (publ) Assets
Year Assets Growth
2012 462.198.000
2013 484.982.000 4.7%
2014 1.005.785.000 51.78%
2015 1.059.242.999 5.05%
2016 1.250.491.000 15.29%
2017 1.422.424.000 12.09%
2018 1.697.467.000 16.2%
2019 2.138.687.000 20.63%
2020 2.305.089.000 7.22%
2021 19.429.000.000 88.14%
2022 20.551.000.000 5.46%
2023 21.180.000.000 2.97%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Vitrolife AB (publ) Liabilities
Year Liabilities Growth
2012 183.216.000
2013 169.452.000 -8.12%
2014 303.214.000 44.11%
2015 214.271.000 -41.51%
2016 230.107.000 6.88%
2017 193.775.000 -18.75%
2018 201.255.000 3.72%
2019 341.059.000 40.99%
2020 288.075.000 -18.39%
2021 4.088.000.000 92.95%
2022 3.811.000.000 -7.27%
2023 3.749.000.000 -1.65%

Vitrolife AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
25.57
Net Income per Share
2.97
Price to Earning Ratio
101.38x
Price To Sales Ratio
11.77x
POCF Ratio
54.27
PFCF Ratio
59.5
Price to Book Ratio
2.34
EV to Sales
11.55
EV Over EBITDA
37.82
EV to Operating CashFlow
53.23
EV to FreeCashFlow
58.36
Earnings Yield
0.01
FreeCashFlow Yield
0.02
Market Cap
40,75 Bil.
Enterprise Value
39,98 Bil.
Graham Number
92.74
Graham NetNet
-17.62

Income Statement Metrics

Net Income per Share
2.97
Income Quality
1.87
ROE
0.02
Return On Assets
0.02
Return On Capital Employed
0.03
Net Income per EBT
0.77
EBT Per Ebit
0.76
Ebit per Revenue
0.2
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0.06
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.56
Operating Profit Margin
0.2
Pretax Profit Margin
0.15
Net Profit Margin
0.12

Dividends

Dividend Yield
0
Dividend Yield %
0.28
Payout Ratio
0.29
Dividend Per Share
0.85

Operating Metrics

Operating Cashflow per Share
5.55
Free CashFlow per Share
5.06
Capex to Operating CashFlow
-0.09
Capex to Revenue
-0.02
Capex to Depreciation
-0.17
Return on Invested Capital
0.03
Return on Tangible Assets
0.17
Days Sales Outstanding
50.61
Days Payables Outstanding
38.73
Days of Inventory on Hand
107.41
Receivables Turnover
7.21
Payables Turnover
9.42
Inventory Turnover
3.4
Capex per Share
-0.49

Balance Sheet

Cash per Share
5,75
Book Value per Share
128,73
Tangible Book Value per Share
-10.24
Shareholders Equity per Share
128.73
Interest Debt per Share
14.34
Debt to Equity
0.11
Debt to Assets
0.09
Net Debt to EBITDA
-0.74
Current Ratio
3.06
Tangible Asset Value
-1,39 Bil.
Net Current Asset Value
-1,92 Bil.
Invested Capital
0.11
Working Capital
1,23 Bil.
Intangibles to Total Assets
0.89
Average Receivables
0,51 Bil.
Average Payables
0,19 Bil.
Average Inventory
451000000
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Vitrolife AB (publ) Dividends
Year Dividends Growth
2009 0
2010 1 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 100%
2015 2 0%
2016 2 50%
2017 3 0%
2023 1 0%

Vitrolife AB (publ) Profile

About Vitrolife AB (publ)

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

CEO
Ms. Bronwyn Brophy
Employee
1.123
Address
Gustaf Werners gata 2
Gothenburg, 421 32

Vitrolife AB (publ) Executives & BODs

Vitrolife AB (publ) Executives & BODs
# Name Age
1 Guillermo Ferrando
Vice President Strategy & Corporate development
70
2 Ms. Karin Koritz Russberg
Senior Vice President of HR & Sustainability
70
3 Ms. Bronwyn Brophy
Chief Executive Officer
70
4 Mr. Patrik Tolf
Chief Financial Officer
70
5 Mr. Claus Bisgaard
Senior Vice President of Technologies
70
6 Mr. Rickard Ericsson
Senior Vice President of Global Sales & Marketing
70
7 Ricardo Capella
Senior Vice President Genetic Services
70

Vitrolife AB (publ) Competitors